Abstract
Obesity arises from an impairment of energy homeostasis, which essentially involves the balance of food intake and energy dissipation. Some secreted molecules in the hypothalamus have become the focus of recent attention for their important roles in the regulation of food intake. One such molecule, nesfatin-1, is a novel molecule originally expressed in the hypothalamic nuclei of the brain, which exerts its satiety function in conjunction with other molecules, including oxytocin and pro-opiomelanocortin (POMC). Nesfatin-1 is processed from its precursor, DNA binding/EF-hand/acidic protein (NEFA)/nucleobindin 2 (NUCB2), and its mRNA is unexpectedly stabilized by troglitazone, a ligand for peroxisome proliferator-activated receptor γ (PPARγ). Subsequent analyses and observations have demonstrated that nesfatin-1 is also located in brain nuclei outside the hypothalamus and in peripheral tissues, and that nesfatin-1 neurons in the brain receive several signals. These findings imply that nesfatin-1 is an endogenous molecule important for the regulation of not only food intake but also other physiological functions. We discuss what is currently known about nesfatin-1, including new developments in our understanding of its distribution, regulation, and biological function.
Keywords: Nesfatin-1, NUCB2, food intake, hypothalamus, pancreas, PPARγ.
Current Pharmaceutical Design
Title:Discovery of Nesfatin-1 and Overview of Biological Actions and New Developments
Volume: 19 Issue: 39
Author(s): Masatomo Mori, Masanobu Yamada, Shuichi Okada, Koshi Hashimoto, Tesurou Satoh, Hiroyuki Shimizu and Toshihiko Yada
Affiliation:
Keywords: Nesfatin-1, NUCB2, food intake, hypothalamus, pancreas, PPARγ.
Abstract: Obesity arises from an impairment of energy homeostasis, which essentially involves the balance of food intake and energy dissipation. Some secreted molecules in the hypothalamus have become the focus of recent attention for their important roles in the regulation of food intake. One such molecule, nesfatin-1, is a novel molecule originally expressed in the hypothalamic nuclei of the brain, which exerts its satiety function in conjunction with other molecules, including oxytocin and pro-opiomelanocortin (POMC). Nesfatin-1 is processed from its precursor, DNA binding/EF-hand/acidic protein (NEFA)/nucleobindin 2 (NUCB2), and its mRNA is unexpectedly stabilized by troglitazone, a ligand for peroxisome proliferator-activated receptor γ (PPARγ). Subsequent analyses and observations have demonstrated that nesfatin-1 is also located in brain nuclei outside the hypothalamus and in peripheral tissues, and that nesfatin-1 neurons in the brain receive several signals. These findings imply that nesfatin-1 is an endogenous molecule important for the regulation of not only food intake but also other physiological functions. We discuss what is currently known about nesfatin-1, including new developments in our understanding of its distribution, regulation, and biological function.
Export Options
About this article
Cite this article as:
Mori Masatomo, Yamada Masanobu, Okada Shuichi, Hashimoto Koshi, Satoh Tesurou, Shimizu Hiroyuki and Yada Toshihiko, Discovery of Nesfatin-1 and Overview of Biological Actions and New Developments, Current Pharmaceutical Design 2013; 19 (39) . https://dx.doi.org/10.2174/138161281939131127123527
DOI https://dx.doi.org/10.2174/138161281939131127123527 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Periodontitis and Redox Status: A Review
Current Pharmaceutical Design Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Mechanisms of Liver Injury: An Overview
Current Molecular Medicine Current Issues with Glycoprotein IIb-IIIa Antagonists
Current Drug Targets The Application of Mechanical Aerosol Delivery Systems in an in vitro Model of Mechanically Ventilated Neonates
Recent Patents on Drug Delivery & Formulation Renin-angiotensin System Blockers and Modulation of Radiation-Induced Brain Injury
Current Drug Targets Carbon Monoxide: Medicinal Chemistry and Biological Effects
Current Medicinal Chemistry Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews GDF11 Attenuated ANG II-Induced Hypertrophic Cardiomyopathy and Expression of ANP, BNP and Beta-MHC Through Down- Regulating CCL11 in Mice
Current Molecular Medicine The Role of N-Acetylcysteine in Platelet Aggregation and Reperfusion Injury in Recent Years
Current Clinical Pharmacology Immunosuppression in Sepsis
Current Pharmaceutical Design Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Atomoxetine Protects Against NMDA Receptor-mediated Hippocampal Neuronal Death Following Transient Global Cerebral Ischemia
Current Neurovascular Research Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Gastric Cytoprotection Beyond Prostaglandins: Cellular and Molecular Mechanisms of Gastroprotective and Ulcer Healing Actions of Antacids
Current Pharmaceutical Design Oxidative Stress and the Use of Antioxidants for the Treatment of Rheumatoid Arthritis
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Curcumin Alleviates Cerebral Ischemia-reperfusion Injury by Inhibiting NLRP1-dependent Neuronal Pyroptosis
Current Neurovascular Research Multifunctional RNase MCPIP1 and its Role in Cardiovascular Diseases
Current Medicinal Chemistry Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets